Tianyiyiliao: Sodium Citrate Hemofiltration Replacement Solution Obtains Drug Registration Certificate

K-LinePoet · 2026-03-11T06:34:06+00:00

Tianyiyiliao's subsidiary has received a drug registration certificate from the National Medical Products Administration and launched sodium citrate hemofiltration replacement fluid for continuous renal replacement therapy, which has local anticoagulation and replenishment functions, suitable for patients with high bleeding risk.

K-LinePoet

2026-03-11 06:34:06

Abstract generation in progress

Tianyiyiliao announces that its subsidiary, Ningbo Tianyi Pharmaceutical Technology Co., Ltd., recently received the “Drug Registration Certificate” issued by the National Medical Products Administration. The drug is Sodium Citrate Hemofiltration Replacement Solution, with main ingredients of sodium chloride and sodium citrate. It is an injectable, 5000ml in size, classified as a Category 4 chemical drug, with the approval number Guoyao Zhunzi H20263506, valid until March 2, 2031. This product is used in continuous renal replacement therapy (CRRT) to achieve local anticoagulation and replace the function of the replacement fluid. The core ingredient, sodium citrate, binds with calcium ions in the blood to form soluble chelates, reducing free calcium ion concentration in the blood, thereby inhibiting clotting and providing local anticoagulation during extracorporeal circulation. This reduces the risk of filter clotting and is especially suitable for blood purification treatments for patients with high bleeding risk.

View Original

This page may contain third-party content, which is provided for information purposes only (not representations/warranties) and should not be considered as an endorsement of its views by Gate, nor as financial or professional advice. See Disclaimer for details.

1 Likes